EI
MRSN

EAM Investors’s Mersana Therapeutics MRSN Stock Holding History

EAM Investors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,750
Closed -$2.19M – 328
2020
Q2 		$2.19M Buy
+3,750
New +$1.28M 0.48% 65

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EAM Investors's MRSN Position: Q3 2020 in Review

EAM Investors sold out of Mersana Therapeutics (MRSN) in Q3 2020, closing a stake of 3,750 shares — an estimated $2.19M sold.

EAM Investors first reported a position in MRSN in Q2 2020 and held it in 1 quarter. The position peaked at $2.19M in Q2 2020. 135 funds tracked by Wall St. Rank hold MRSN as of Q3 2020.

  • EAM Investors reported no remaining Mersana Therapeutics position as of Q3 2020 after selling out during the quarter.
  • EAM Investors sold 3,750 Mersana Therapeutics shares in Q3 2020, an estimated $2.19M.
  • EAM Investors first reported a position in Mersana Therapeutics in Q2 2020 and held it in 1 quarter.
  • EAM Investors's Mersana Therapeutics position peaked at $2.19M in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.